TDMS Study 05035-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
4-HYDROXYACETANILIDE
NTP Experiment-Test: 05035-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
Facility: TSI Mason Research
Chemical CAS #: 103-90-2
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.06% LF 0.3% MF 0.6% HF
UF
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund 21 9 21 8
Dead 2 9 4
Accident 4
Survivors
Terminal Sacrifice 27 32 25 38
Animals Examined Microscopically 50 50 50 51
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (45) (44) (46)
Intestine Large, Cecum (49) (45) (49) (48)
Sarcoma 1 (2%)
Intestine Small, Duodenum (48) (44) (47) (50)
Hemangiosarcoma 1 (2%)
Intestine Small, Ileum (48) (43) (48) (47)
Intestine Small, Jejunum (47) (42) (46) (48)
Adenocarcinoma 1 (2%)
Liver (49) (50) (50) (49)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Intestine Small 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 3 (6%) 4 (8%) 7 (14%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Mesentery (4) (4) (3) (1)
Pancreas (49) (48) (47) (49)
Salivary Glands (46) (49) (50) (50)
Stomach, Forestomach (48) (49) (49) (48)
Stomach, Glandular (47) (47) (50) (48)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.06% LF 0.3% MF 0.6% HF
UF
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (49) (46) (49)
Adrenal Gland, Medulla (46) (46) (45) (47)
Pheochromocytoma Malignant 1 (2%)
Islets, Pancreatic (48) (47) (43) (49)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (46) (43) (42) (45)
Pars Distalis, Adenoma 14 (30%) 16 (37%) 7 (17%) 14 (31%)
Pars Distalis, Carcinoma 1 (2%) 1 (2%) 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (48) (50) (50) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 2 (4%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (47) (49) (49) (50)
Cystadenoma 2 (4%) 1 (2%)
Hemangioma 1 (2%)
Uterus (49) (50) (50) (49)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%) 1 (2%)
Endometrium, Adenocarcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (49) (49)
Lymph Node (49) (47) (49) (49)
Lymph Node, Mandibular (41) (26) (29) (44)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (44) (45) (45) (43)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Spleen (49) (50) (50) (49)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (23) (30) (30) (34)
Page 3
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.06% LF 0.3% MF 0.6% HF
UF
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (25) (20) (28) (17)
Adenoacanthoma 1 (5%)
Adenocarcinoma 1 (4%) 1 (6%)
Skin (47) (48) (49) (48)
Hemangiosarcoma 1 (2%)
Melanoma Malignant 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 4 (8%) 4 (8%) 4 (8%)
Carcinoma, Metastatic 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Nose (47) (44) (45) (38)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1) (1)
Carcinoma, Metastatic 1 (100%)
Harderian Gland (5) (2) (2) (2)
Adenoma 4 (80%) 2 (100%) 1 (50%) 2 (100%)
Carcinoma 1 (20%) 1 (50%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.06% LF 0.3% MF 0.6% HF
UF
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (49) (50) (49)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (49) (46) (44) (46)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(51)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Leukemia 1 (2%) 1 (2%)
Lymphoma Malignant 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 2 (4%) 3 (6%) 3 (6%)
Lymphoma Malignant Mixed 8 (16%) 6 (12%) 7 (14%) 13 (25%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 0.06% LF 0.3% MF 0.6% HF
UF
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 28 24 35
Total Primary Neoplasms 45 48 37 49
Total Animals with Benign Neoplasms 22 22 17 22
Total Benign Neoplasms 24 32 22 26
Total Animals with Malignant Neoplasms 20 15 14 19
Total Malignant Neoplasms 21 16 15 23
Total Animals with Metastatic Neoplasms 1 1 2 1
Total Metastatic Neoplasm 1 1 3 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.06% LM 0.3% MM 0.6% HM
UM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund 13 3 16 10
Dead 5 7 3 9
Survivors
Terminal Sacrifice 32 40 31 31
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (41) (43) (47) (40)
Intestine Small, Duodenum (48) (42) (49) (45)
Adenocarcinoma 1 (2%)
Intestine Small, Ileum (48) (45) (48) (44)
Intestine Small, Jejunum (47) (43) (47) (45)
Adenocarcinoma 1 (2%) 2 (4%)
Liver (50) (50) (50) (50)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%) 1 (2%)
Hepatocellular Carcinoma 7 (14%) 1 (2%) 6 (12%) 3 (6%)
Hepatocellular Adenoma 11 (22%) 8 (16%) 5 (10%) 4 (8%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Pancreas (47) (49) (50) (48)
Salivary Glands (50) (49) (50) (49)
Stomach, Forestomach (49) (49) (50) (49)
Squamous Cell Papilloma 1 (2%) 3 (6%) 2 (4%)
Stomach, Glandular (50) (47) (49) (48)
Adenocarcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.06% LM 0.3% MM 0.6% HM
UM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (50) (48) (49) (49)
Capsule, Adenoma 1 (2%)
Subcapsular, Adenoma 1 (2%)
Adrenal Gland, Cortex (50) (48) (49) (49)
Adrenal Gland, Medulla (47) (48) (48) (48)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 4 (8%) 1 (2%) 1 (2%)
Pituitary Gland (48) (39) (39) (46)
Thyroid Gland (49) (49) (50) (50)
Follicular Cell, Adenoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Follicular Cell, Adenoma, Multiple 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Prostate (48) (42) (47) (48)
Seminal Vesicle (49) (49) (49) (50)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50) (49)
Lymph Node (49) (47) (47) (47)
Axillary, Fibrosarcoma, Metastatic 1 (2%)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%)
Renal, Histiocytic Sarcoma 1 (2%)
Lymph Node, Mandibular (43) (20) (17) (40)
Lymph Node, Mesenteric (43) (45) (47) (42)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Spleen (50) (50) (49) (48)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%)
Histiocytic Sarcoma 1 (2%)
Thymus (11) (18) (28) (22)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.06% LM 0.3% MM 0.6% HM
UM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (48) (49) (50) (50)
Basal Cell Carcinoma 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 2 (4%)
Trichoepithelioma 1 (2%)
Subcutaneous Tissue, Fibroma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 5 (10%) 5 (10%) 3 (6%) 6 (12%)
Subcutaneous Tissue, Lipoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Peripheral Nerve (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 5 (10%) 5 (10%) 9 (18%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%)
Cholangiocarcinoma, Metastatic, Liver 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 2 (4%) 2 (4%)
Nose (47) (40) (46) (44)
Squamous Cell Papilloma 1 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Neurofibroma 1 (100%)
Harderian Gland (4) (3) (4) (3)
Adenoma 4 (100%) 2 (67%) 3 (75%) 3 (100%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.06% LM 0.3% MM 0.6% HM
UM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50) (50)
Histiocytic Sarcoma 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%)
Urinary Bladder (47) (46) (46) (45)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 6 (12%) 3 (6%) 2 (4%) 2 (4%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05035-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 4-HYDROXYACETANILIDE Date: 09/04/94
Route: DOSED FEED Time: 22:25:10
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 0.06% LM 0.3% MM 0.6% HM
UM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 29 31 28
Total Primary Neoplasms 56 41 46 37
Total Animals with Benign Neoplasms 23 22 21 20
Total Benign Neoplasms 29 25 28 22
Total Animals with Malignant Neoplasms 25 14 17 13
Total Malignant Neoplasms 27 16 18 15
Total Animals with Metastatic Neoplasms 4 3 6
Total Metastatic Neoplasm 5 3 6
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 61662-61662/61662
--multipart-boundary--